Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (412)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 1 to 50 of 424
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Technology appraisal guidance
12 February 2025
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Technology appraisal guidance
TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Technology appraisal guidance
20 August 2025
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339
Technology appraisal guidance
2 July 2025
Advanced breast cancer: diagnosis and management (Partial update)
NICE guideline
TBC
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension
Interventional procedures guidance
5 February 2025
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
Technology appraisal guidance
13 November 2024
ALXN1840 for treating Wilson disease TS ID 9950
Technology appraisal guidance
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
Technology appraisal guidance
30 April 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256
Technology appraisal guidance
20 August 2025
Amyotrophic lateral sclerosis - SAR443820 [ID6386]
Technology appraisal guidance
TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Technology appraisal guidance
11 December 2024
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Technology appraisal guidance
TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Highly specialised technology
TBC
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway
Health technology evaluation
19 December 2024
Artificial intelligence software to help detect and characterise colorectal polyps
Diagnostics guidance
TBC
Artificial intelligence technologies to help detect fractures on X-rays in urgent care
Health technology evaluation
14 January 2025
Asthma: diagnosis, monitoring and chronic asthma management
NICE guideline
27 November 2024
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]
Technology appraisal guidance
23 July 2025
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]
Technology appraisal guidance
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
6 November 2024
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Technology appraisal guidance
25 June 2025
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour
Interventional procedures guidance
16 April 2025
Bed frames for adults in acute settings
Health technology evaluation
28 May 2025
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Technology appraisal guidance
19 March 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Technology appraisal guidance
TBC
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266
Technology appraisal guidance
16 July 2025
Current page
1
2
3
…
9
Page
1
of
9
Next page
Results per page
10
25
50
All
Back to top